Latest News and Press Releases
Want to stay updated on the latest news?
-
TEL-AVIV, Israel, March 22, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily...
-
A first randomized, double-blind, placebo-controlled Phase III clinical study with RHB-104 for the treatment of Crohn’s disease (the MAP US study) is ongoing in the U.S. and additional...
-
PHILADELPHIA, PA--(Marketwired - Mar 20, 2017) - Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose...
-
WASHINGTON, March 14, 2017 (GLOBE NEWSWIRE) -- From New York to Hawaii and Arizona to Florida, the Colon Cancer Alliance and Bayer are partnering to promote colon cancer awareness with the Big Colon...
-
TEL-AVIV, Israel, March 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASEREGULATED...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASEREGULATED...
-
Mechelen, Belgium; 10 March 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing...
-
PHILADELPHIA, PA--(Marketwired - Mar 9, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE TiGenix Announces...